ACT Therapeutics Limited 31/12/2025 iXBRL

ACT Therapeutics Limited

Filleted accounts

31 December 2025

Company registration number: 12541462

ACT Therapeutics Limited

Directors and other information


	Directors	Dr P E Walday
		J L Allis
		Dr M Stromme


	Company number	12541462


	Registered office	The Old Dairy
		12 Stephen Road
		Headington
		Oxford
		OX3 9AY


	Accountants	Cox Hinkins & Co. Limited
		Accountants and Taxation Advisors
		The Old Dairy
		12 Stephen Road
		Headington
		Oxford
		OX3 9AY

ACT Therapeutics Limited

Balance sheet

31st December 2025

		2025		2024
	Note	£	£	£	£

Fixed assets
Tangible assets	5	118,142		102,933
		_______		_______
			118,142		102,933

Current assets
Debtors	6	68,655		96,025
Cash at bank and in hand		7,176		7,659
		_______		_______
		75,831		103,684
Creditors: amounts falling due
within one year	7	( 27,800)		( 5,728)
		_______		_______
Net current assets			48,031		97,956

			_______		_______
Net assets			166,173		200,889
			_______		_______

Capital and reserves
Called up share capital	8		10,000		10,000
Profit and loss account			156,173		190,889
			_______		_______
Shareholder funds			166,173		200,889
			_______		_______

For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the Profit & loss account has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 17 September 2026 , and are signed on behalf of the board by:

Dr P E Walday

Director

Company registration number: 12541462

ACT Therapeutics Limited

Notes to the financial statements

Year ended 31st December 2025

1. General information

The company is a private company limited by shares, registered in England & Wales. The address of the registered office is The Old Dairy, 12 Stephen Road, Headington, Oxford, OX3 9AY. There was no significant change in the company's principal activity during the year which continued to be research and development into developing a technology platform for targeted therapeutic enhancement.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis. The principal accounting policies are set out below. The financial statements are prepared in sterling which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period provided that the outcome can be reliably estimated. When the outcome cannot be reliably estimated, revenue is recognised only to the extent that expenses recognised are recoverable.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is not recognised in respect of any timing differences at the reporting date as all are insignificant. Unrelieved tax losses and other deferred tax assets are not recognised as it is uncertain when they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to profit or loss.

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost of an asset, less its residual value, over the useful economic life of that asset as follows:


Plant and machinery	-	20 %	straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractualarrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 1 (2024: 1 ).

5. Tangible assets

	Plant and machinery	Total
	£	£
Cost
At 1st January 2025	198,000	198,000
Additions	51,500	51,500
	_______	_______
At 31st December 2025	249,500	249,500
	_______	_______
Depreciation
At 1st January 2025	95,067	95,067
Charge for the year	36,291	36,291
	_______	_______
At 31st December 2025	131,358	131,358
	_______	_______
Carrying amount
At 31st December 2025	118,142	118,142
	_______	_______
At 31st December 2024	102,933	102,933
	_______	_______

6. Debtors

	2025	2024
	£	£
Amounts owed by group undertakings and undertakings in which the company has a participating interest	58,338	96,025
Other debtors	10,317	-
	_______	_______
	68,655	96,025
	_______	_______

7. Creditors: amounts falling due within one year

	2025	2024
	£	£
Trade creditors	25,900	5,577
Social security and other taxes	400	151
Other creditors	1,500	-
	_______	_______
	27,800	5,728
	_______	_______

8. Called up share capital

Issued, called up and fully paid

	2025		2024
	No	£	No	£
Ordinary shares of £ 1.00 each	10,000	10,000	10,000	10,000
	_______	_______	_______	_______

9. Controlling party

ACT Therapeutics Limited is a wholly owned subsidiary of EXACT Therapeutics AS , whose registered office is Østre Aker vei 19, 0581 Oslo, Norway.